Pharma BD Deal Intelligence

Rani Therapeutics Holdings, Inc. / PegBio Co., Ltd.

2026 · Co-Development · Complete

Rani Therapeutics and PegBio entered a research and development collaboration to develop oral RaniPill formulations of multiple candidates from PegBio's obesity and metabolic disease portfolio, including multi-target metabolic regulatory and long-acting assets. The parties intend to advance the most promising candidates into clinical development and explore joint research, manufacturing and commercialization opportunities outside China; financial terms were not disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals